Simponi approved for ulcerative colitis

May 15, 2013

(HealthDay)—Simponi (golimumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe ulcerative colitis.

The drug is designed to block , which has a key role in causing abnormal inflammation and , the FDA said Wednesday in a news release.

The drug has already been approved to treat psoriatic arthritis, rheumatoid arthritis and , the agency said.

Ulcerative colitis, affecting some 620,000 Americans, causes chronic inflammation and ulcers in the inner lining of the large intestine. Common symptoms include abdominal discomfort, gastrointestinal bleeding and diarrhea.

Simponi was clinically evaluated in two studies involving more than 800 people. The most common side effects reported were upper respiratory infection and redness at the injection site. People treated with the drug are at greater-than-average risk of contracting several types of infection, lymphoma, heart failure, nervous system disorders and allergic reactions, the FDA said.

The drug is marketed by Janssen Ortho Biotech Inc., based in Horsham, Pa.

Explore further: Humira's approval widened to include ulcerative colitis

More information: Medline Plus has more about ulcerative colitis.

Related Stories

Xeljanz approved for rheumatoid arthritis

November 7, 2012

(HealthDay)—Xeljanz (tofacitinib) has been approved by the U.S. Food and Drug Administration to treat symptoms of rheumatoid arthritis (RA) among people who can't tolerate, or haven't been helped by, the drug methotrexate.

FDA approves Procysbi for nephropathic cystinosis

May 2, 2013

(HealthDay)—Procysbi (cysteamine bitartrate) delayed-release capsules have been approved by the U.S. Food and Drug Administration to treat nephropathic cystinosis in children (6 years and up) and adults. Since it is intended ...

Gattex approved for short bowel syndrome

December 22, 2012

(HealthDay)—Gattex (teduglutide) has been approved by the U.S. Food and Drug Administration to treat nutritional problems caused by short bowel syndrome.

Pomalyst approved for advanced multiple myeloma

February 9, 2013

(HealthDay)—Pomalyst (pomalidomide) has been approved by the U.S. Food and Drug Administration to treat cases of multiple myeloma that have not responded to other therapies.

Recommended for you

Researchers identify source of opioids' side effects

January 17, 2017

A commercially available drug may help drastically reduce two side effects of opioid painkillers—a growing tolerance and a paradoxical increased sensitivity to pain—without affecting the drugs' ability to reduce pain, ...

CVS generic competitor to EpiPen, sold at a 6th the price

January 12, 2017

CVS is now selling a rival, generic version of Mylan's EpiPen at about a sixth of its price, just months after the maker of the life-saving allergy treatment was eviscerated before Congress because of its soaring cost to ...

Many misuse OTC sleep aids: survey

December 29, 2016

(HealthDay)—People struggling with insomnia often turn to non-prescription sleep remedies that may be habit-forming and are only intended for short-term use, according to a new Consumer Reports survey.

The pill won't kill your sexual desire, researchers say

December 15, 2016

Taking the pill doesn't lower your sexual desire, contrary to popular belief, according to research published in the Journal of Sexual Medicine. The authors of the research, from the University of Kentucky and Indiana University ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.